NDT Pharmaceuticals Inc (NDTP)

[Aquahoya]

Michael W. Fountain - Member of CCA


About:

OK folks, while we wait for new news on MILV, it is time visit old news that no one seems to know about, on MILV and the company taking it over, CCA.

We hired Sherlock Aqua-Holms, and Doctor Watson the Drugman and Myself to dig up the real story.

After 160 combined hours of digging the last 6 days, we hit paydirt.

There be Gold in them thar hills folks!!!! Black gold, LOL

If you want to know why there has been so much buying in the face of sheer panic/fear, we must start with a central figure, who looks like a cloned Elon Musk???

His name is Michael W Fountain.

31 issued US patents. Holly COW????

100 International issued patents! Seriously???

180 international Products using his patents!!!! Indeed!!!!

One patented Michael W Fountain product coming our way (based on historical DD), called a Lyposome, is a Star Trek Next Generation Borg Nano-probe with smart bombs as small as 20 nM???

Lyposomes that can cross the blood brain barrier (no simple task gentlemen and ladies) and fix broke shit, LOL in laymen language, in the brain!!!!!

Brain trauma nano probe repair crews in a pill?????

What is that worth folks?

1 Billion dollars?

Let the bidding begin folks.

MILV is the ticker!!!!

https://patents.justia.com/patent/9987234
https://www.usf.edu/business/contacts/fountain-michael.aspx

US Patent for Nanolipidic particle assembly populations Patent

(Patent # 9,987,234)

Nanolipidic particle assembly populations
Oct 27, 2016 -

Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution.

NLPs can be loaded with a desired passenger molecule.

Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size.

Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm.

A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency.

NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.

----------------------------------------------------------------------

Book in Liposomes:

https://books.google.com/books?id=PBalDwAAQBAJ&pg=PT280&lpg=PT280&dq=michael+w+fountain,+liposome&source=bl&ots=Hb8rQOwoSQ&sig=ACfU3U20O5isYke1ol3VCqHMiGYXFMoi_A&hl=en&sa=X&ved=2ahUKEwibss7WydXlAhUlm-AKHYrFAhwQ6AEwBHoECAkQAQ#v=onepage&q=michael

----------------------------------------------------------------------

Companies he consults and innovator for that we can find as of now:

Celazone Our Team

https://celazomeskin.com/pages/our-team


DermaCM Advisory board

http://dermacm.com/drfountain.html

Former Michael W Fountain FDA applications

http://510k.medevnet.com/applications/index.cfm?fuseaction=list&contact=MICHAEL%20%20FOUNTAIN%2CPHD

----------------------------------------------------------------------

Some more light reading:

What to expect from milv

Quote:
CCA can COMMERCIALLY create nano-scale particles that can cross the blood/brain barrier into brain cell issue to heal traumatic brain injury.


https://www.facebook.com/Compelling-Competitive-Advantage-LLC-159542474411149/

Form SC 13D Fountain Michael W.
SC 13D - General statement of acquisition of beneficial ownership

https://sec.report/Document/0001144204-16-138968/

"Item 3.Source and Amount of Funds or Other Consideration

"The Reporting Person acquired his 100,000 shares of Series A Preferred Stock in a private placement on November 2, 2016 when Endeavor IP, Inc. entered into an Exclusive License Agreement with Compelling Competitive Advantage, LLC (“CCA”) in which he has been a member since its inception in September 2013. No cash was required for this issuance of shares of Common Stock in exchange for the intellectual property of CCA."